Prokidney CORP 8-K filings

ProKidney Corp. stockholders re-elected three directors and ratified the appointment of Ernst & Young LLP as the independent auditor for 2026.

ProKidney Corp. announced its first quarter 2026 financial results, highlighting progress in its Phase 3 PROACT 1 study for chronic kidney disease and maintaining a cash runway into mid-2027.

ProKidney Corp. announced its full year 2025 financial results, highlighting progress in its Phase 3 PROACT 1 study for rilparencel and confirming FDA alignment on an accelerated approval pathway.

ProKidney Corp. updated its investor presentation, highlighting positive Phase 2 data, FDA alignment on an accelerated approval pathway for rilparencel, and progress in its pivotal Phase 3 PROACT 1 study with topline results expected in Q2 2027.

ProKidney Corp. reported its third-quarter 2025 financial results, highlighting positive Phase 2 clinical data for rilparencel and FDA alignment on an accelerated approval pathway for its Phase 3 study, with cash reserves projected into mid-2027.

ProKidney Corp. has entered into a new definitive agreement to sell its Greensboro, North Carolina property to Northpoint Development, LLC for approximately $19.1 million in cash.

ProKidney reports positive Phase 2 results and FDA alignment for accelerated approval of rilparencel, extending cash runway into mid-2027.

ProKidney Corp. has completed its corporate domestication from the Cayman Islands to Delaware and restructured its subsidiary entities, streamlining its corporate governance and operational framework.

ProKidney Corp. announced FDA alignment on the accelerated approval pathway for its lead cellular therapy, rilparencel, for patients with advanced chronic kidney disease and type 2 diabetes, with topline data for accelerated approval anticipated in Q2 2027.

ProKidney Corp. has entered into a new Open Market Sale Agreement with Jefferies LLC, enabling the company to sell up to $200 million of its Class A common stock through an at-the-market offering.

ProKidney Corp. announced positive topline results from its Phase 2 REGEN-007 trial, demonstrating statistically significant and clinically meaningful improvement in kidney function for patients with chronic kidney disease and diabetes, and confirmed an upcoming FDA meeting to advance its accelerated approval pathway.

ProKidney Corp. has successfully completed its planned domestication from the Cayman Islands to Delaware, alongside a significant corporate restructuring and the amendment of key governance and financial agreements, effective July 1, 2025.

ProKidney Corp. has successfully completed its corporate domestication, changing its jurisdiction of incorporation from the Cayman Islands to Delaware, a move approved by shareholders.

ProKidney Corp. shareholders overwhelmingly approved the company's reincorporation from the Cayman Islands to Delaware and adopted a new corporate charter at its 2025 Annual General Meeting.

ProKidney announced its Q1 2025 financial results, highlighting progress on its rilparencel clinical trials and regulatory pathway.

ProKidney announces its full year 2024 financial results, highlighting progress in its Phase 3 program, positive Phase 2 data, manufacturing restart, and securing $140 million in equity, extending its cash runway into mid-2027.

ProKidney Corp. has entered into an agreement to sell its real property in Greensboro, North Carolina, for approximately $20.5 million in cash.

ProKidney Corp. has entered into an agreement to purchase two buildings in Winston-Salem, North Carolina, for $22.5 million to support manufacturing of its lead product candidate.

ProKidney announced positive regulatory feedback from the FDA regarding their Phase 3 trial for rilparencel, along with their third quarter 2024 financial results.

ProKidney has updated its Phase 3 program for rilparencel, discontinuing the ex-U.S. trial to focus on U.S. approval, with topline results expected by Q3 2027.

ProKidney Corp. reported positive interim data for its REGEN-007 study, restarted manufacturing and Phase 3 trials, and closed a $140 million public offering, extending its cash runway into mid-2026.

ProKidney Corp. has announced the pricing of a $130 million public offering and a concurrent registered direct offering of its Class A ordinary shares.

ProKidney's REGEN-007 Phase 2 trial shows promising interim results with stabilized kidney function for 18 months, alongside the resumption of manufacturing and Phase 3 trials.

ProKidney Corp. held its 2024 Annual General Meeting, electing two directors and ratifying the appointment of Ernst & Young LLP as its independent auditor.

ProKidney Corp. released final data from its Phase 2 RMCL-002 clinical trial, showing potential for its rilparencel treatment to preserve kidney function, particularly in high-risk patients.

ProKidney reported its Q1 2024 financial results, provided business updates, and announced key milestones for its clinical programs.

ProKidney Corp. has appointed Ulrich Ernst as Executive Vice President of Technical Operations, effective March 25, 2024, to bolster its leadership team.

ProKidney announced its full year 2023 financial results, highlighting clinical progress and corporate updates, including a focus on higher-risk patients for their Phase 3 trial.

ProKidney Corp. has finalized a separation agreement with its former Chief Operating Officer, Deepak Jain, including severance pay, bonus eligibility, and extended health benefits.

ProKidney Corp. has finalized a separation agreement with its former CEO, Tim Bertram, Ph.D., including severance pay, bonus eligibility, and extended health insurance coverage.